Susquehanna Maintains Negative on RXO, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 53.1%

Neg 0% Neu 0% Pos 53.1%

Susquehanna analyst Bascome Majors maintains RXO (NYSE:RXO) with a Negative and raises the price target from $12 to $14.